gabapentin has been researched along with Down Syndrome in 2 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects." | 5.38 | Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012) |
| " As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects." | 1.38 | Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vidal, V | 1 |
| García, S | 1 |
| Martínez, P | 1 |
| Corrales, A | 1 |
| Flórez, J | 1 |
| Rueda, N | 1 |
| Sharma, A | 1 |
| Martínez-Cué, C | 1 |
| Solaro, C | 1 |
| Uccelli, MM | 1 |
| Mancardi, GL | 1 |
2 other studies available for gabapentin and Down Syndrome
| Article | Year |
|---|---|
Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cognition; Cyclohexanecarboxylic Acids; Disease | 2012 |
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis | 1999 |